size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair®) treatment

• Published in: Allergy (Copenhagen) 2009-10, Vol.64 (10), p.1472-1477
• Main Authors: Johansson, S.G.O, Nopp, A, Öman, H, Ankerst, J, Cardell, L.O, Grönneberg, R, Matsols, H, Rudblad, S, Strand, V, Stålenheim, G
• Format: Article
• Language: English
• Subjects: Allergens - immunology; Allergies; Animals; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - therapeutic use; Antibodies, Anti-Idiotypic - administration & dosage; Antibodies, Anti-Idiotypic - therapeutic use; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Asthma; basophils; Basophils - immunology; Biological and medical sciences; Cats; Cats - immunology; CD-sens; Clinical Medicine; Clinical trials; Conjunctivitis, Allergic - drug therapy; Conjunctivitis, Allergic - etiology; Conjunctivitis, Allergic - immunology; Dermatology; Double-Blind Method; Drug therapy; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; IgE; Immunoglobulin E - blood; Immunoglobulin E - immunology; Klinisk medicin; Lungmedicin och allergi; Medical and Health Sciences; Medical sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Omalizumab; Predictive Value of Tests; Respiratory Medicine and Allergy; responders; Rhinitis, Allergic, Seasonal - drug therapy; Rhinitis, Allergic, Seasonal - etiology; Rhinitis, Allergic, Seasonal - immunology; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Treatment Outcome
• ISSN: 0105-4538; 1398-9995; 1398-9995
• DOI: 10.1111/j.1398-9995.2009.02051.x

Some patients with allergic asthma treated with anti-IgE (Xolair®) do not become symptom free. Better criteria for response assessment than allergy skin tests or IgE determination are needed. The impact of the size of the disease relevant allergen-specific IgE antibody fraction, i.e. the percentage of IgE antibody of total IgE, was evaluated in cat allergic patients treated with the recommended doses of Xolair®. Results were measured as changes in basophil allergen threshold sensitivity (CD-sens). In a double-blind placebo controlled trial 20 patients with a high (>3.8%) and 18 with a low (